Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2006 1
2009 1
2010 1
2019 1
2020 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study.
Olcucu MT, Teke K, Yildirim K, Toğac M, Işık B, Yilmaz YC. Olcucu MT, et al. Int Braz J Urol. 2020 Mar-Apr;46(2):185-193. doi: 10.1590/S1677-5538.IBJU.2019.0094. Int Braz J Urol. 2020. PMID: 32022506 Free PMC article.
OBJECTIVE: To evaluate the effects of solifenacin, darifenacin, and propiverine on nasal-, subfoveal-, temporal choroidal thicknesses (NCT, SFCT, TCT), intraocular pressure (IOP) and pupil diameter (PD). MATERIALS AND METHODS: Patients with overactive bladder (OAB) …
OBJECTIVE: To evaluate the effects of solifenacin, darifenacin, and propiverine on nasal-, subfoveal-, temporal choroidal thicknesses …
Treatment of dysautonomia associated with Parkinson's disease.
Mostile G, Jankovic J. Mostile G, et al. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S224-32. doi: 10.1016/S1353-8020(09)70820-X. Parkinsonism Relat Disord. 2009. PMID: 20082997
Non-motor symptoms are increasingly recognized to adversely impact on the quality of life of patients with in Parkinson's disease (PD), particularly as the disease progresses. Autonomic symptom severity in patients with PD seems to correlate with older age, greater …
Non-motor symptoms are increasingly recognized to adversely impact on the quality of life of patients with in Parkinson's disease (PD …
Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR. Bayes M, et al. Methods Find Exp Clin Pharmacol. 2006 Jul-Aug;28(6):379-412. Methods Find Exp Clin Pharmacol. 2006. PMID: 16894408 Clinical Trial.
This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, ademetionine, AG-7352, alemtuzumab, Amb a 1 ISS-DNA, anakinra, apaziquone, aprepitant, aripiprazole, atazanavir sulfate; BAL-8557, bevacizumab, …
This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, adem …
Novel regulatory systems for acetylcholine release in rat striatum and anti-Alzheimer's disease drugs.
Muramatsu I, Uwada J, Yoshiki H, Sada K, Lee KS, Yazawa T, Taniguchi T, Nishio M, Ishibashi T, Masuoka T. Muramatsu I, et al. J Neurochem. 2019 Jun;149(5):605-623. doi: 10.1111/jnc.14701. Epub 2019 May 7. J Neurochem. 2019. PMID: 30968952 Free article.
The autoinhibition induced by released ACh was predominantly suppressed by the M(2) -selective antagonist AF-DX 116, partially inhibited by M(3) -selective darifenacin, and minimally by M(4) -selective PD 102807. Other subtype-selective antagonists had no effect at …
The autoinhibition induced by released ACh was predominantly suppressed by the M(2) -selective antagonist AF-DX 116, partially inhibited by …
Complex actions of neurotensin in ascending and sigmoid colonic muscle: Involvement of enteric mediators.
Azriel Y, Liu L, Burcher E. Azriel Y, et al. Eur J Pharmacol. 2010 Oct 10;644(1-3):195-202. doi: 10.1016/j.ejphar.2010.06.049. Epub 2010 Jul 6. Eur J Pharmacol. 2010. PMID: 20615399
Potency of neurotensin in all regions was similar (pD(2) ~7). Atropine and the selective muscarinic receptor antagonists, methoctramine and darifenacin, had no effect on neurotensin contractions. ...
Potency of neurotensin in all regions was similar (pD(2) ~7). Atropine and the selective muscarinic receptor antagonists, methoctrami …
Evidence for a M(1) muscarinic receptor on the endothelium of human pulmonary veins.
Walch L, Gascard JP, Dulmet E, Brink C, Norel X. Walch L, et al. Br J Pharmacol. 2000 May;130(1):73-8. doi: 10.1038/sj.bjp.0703301. Br J Pharmacol. 2000. PMID: 10781000 Free PMC article.
ACh relaxed venous preparations derived from human lung with a pD(2) value of 5.82+/-0.09 (n=16). In venous preparations where the endothelium had been removed, the ACh relaxations were abolished (n=4). ...The selective muscarinic antagonists (darifenacin (M(3)), hi …
ACh relaxed venous preparations derived from human lung with a pD(2) value of 5.82+/-0.09 (n=16). In venous preparations where the en …
Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle.
Choppin A, Eglen RM. Choppin A, et al. Br J Pharmacol. 2001 Feb;132(4):835-42. doi: 10.1038/sj.bjp.0703901. Br J Pharmacol. 2001. PMID: 11181424 Free PMC article.
In the ciliary muscle, a significant (P<0.01) correlation was obtained with human recombinant m3 and m5 receptors. 4. Darifenacin displayed insurmountable antagonism at receptors in the bladder. At receptors in the ciliary muscle, it exhibited two phases of antagonism, …
In the ciliary muscle, a significant (P<0.01) correlation was obtained with human recombinant m3 and m5 receptors. 4. Darifenacin …